Tags: Drug.
Vedolizumab (trade name Entyvio) is a monoclonal antibody being developed by Millennium Pharmaceuticals Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn’s disease. It binds to integrin α4β7 (LPAM-1 lymphocyte Peyer’s patch adhesion molecule 1). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.